Breaking News Headlines Today | Ground News

See every side of every news story

pharmatimes.com image

News from pharmatimes.com

pharmatimes.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is pharmatimes.com credible or reliable? Our Factuality score answers both of those questions. When it comes to pharmatimes.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about pharmatimes.com

Where is pharmatimes.com located?pharmatimes.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top pharmatimes.com News

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

Germany · Germany

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

60% Center coverage: 5 sources

BERLIN--(BUSINESS WIRE)--Dec 4, 2025-See the Story

$Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma$

Stone County, Missouri · Stone County

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

67% Center coverage: 3 sources

/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today updated results from the Phase 3 CARTITUDE-4 study supporting durable treatment-free remissions...See the Story

What's Going On With GRI Bio Stock Thursday? - GRI Bio (NASDAQ:GRI)

What's Going On With GRI Bio Stock Thursday? - GRI Bio (NASDAQ:GRI)

100% Center coverage: 1 sources

GRI Bio shared promising data from a Phase 2a trial for idiopathic pulmonary fibrosis, a chronic lung disease with no known cause.See the Story

Breaking News Topics Related to pharmatimes.com